GlassScriptPhysician profile
Hasan A Rizvi
NPI 1780657148
$6,809.47
in general payments reported to CMS, 2019-2025
56 companies · $1,302 in 2025
The $1,302 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,268 · 2020: $643 · 2021: $921 · 2022: $562 · 2023: $1,662 · 2024: $451 · 2025: $1,302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,162 · Education: $254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,161.71 |
| Education | $253.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,017.47 | 2019-2025 | Erleada, Rybrevant, Balversa |
| Novartis Pharmaceuticals Corporation | $609.20 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $414.31 | 2020-2025 | Calquence, Enhertu, Tagrisso |
| Pfizer INC. | $397.87 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $390.86 | 2019-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $356.03 | 2019-2025 | Opdivo, Reblozyl |
| Myriad Genetic Laboratories, INC. | $308.09 | 2023-2025 | Precisetumor, Bracanalysis Cdx |
| Pharmaessentia USA Corporation | $214.41 | 2023-2025 | Besremi |
| Genzyme Corporation | $213.14 | 2019-2024 | |
| Amgen INC. | $210.72 | 2019-2023 | Lumakras |
| Lilly USA, LLC | $209.83 | 2020-2023 | Retevmo, Jaypirca, Verzenio |
| Janssen Pharmaceuticals, INC | $187.91 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $185.41 | 2019-2023 | Imbruvica |
| Daiichi Sankyo INC. | $139.46 | 2019-2025 | Enhertu |
| Seagen INC. | $128.07 | 2022-2025 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hasan Rizvi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.